RHT
RESONANCE HEALTH LIMITED
$0.0670
▲ +1.52%
Market cap
$32M
Turnover
$20,111
Last price
$0.0670
Day change
+1.52%
Announcements
9
Range, past year
Open 0.040 · Low 0.032 · Now 0.067 · High 0.069
Open RHT in the full dashboard →
Charts, screener, momentum and signals across every ASX-listed code.
RHT momentum and trend analysis
Our analysis
Independent analysis generated by Stock Trade Intelligence
as at 2026-09-28.
Momentum quality
59/100
Wyckoff phase
Uptrend5d
Trend stage
Confirmed Uptrend
1 Day
+1.5%
1 Week
+9.8%
1 Month
+17.5%
1 Year
+67.5%
RSI
67
Avg daily range
4.5%
RESONANCE HEALTH LIMITED scores 59 out of 100 for momentum quality, a reading rated medium confidence. The score weighs trend structure, price consistency, volume backing and how long the move has held, so a high reading means a sustained trend rather than a single large day. Its trend is currently classified as Confirmed Uptrend.
On the Wyckoff cycle it sits in Uptrend, where it has been for 5 trading days. The weekly timeframe reads Uptrend, which agrees with the daily view.
Against the wider market it is currently outperforming and the institutional accumulation signal reads low.
What stands out
- Within 2.9% of 52-week high
- RSI in healthy zone (67)
Points to watch
- Thin liquidity
Browse the whole market by signal:
ASX stocks in Wyckoff accumulationASX momentum stocks by trend qualityASX stocks breaking outASX stocks near 52-week highsRHT announcements
Recent price-sensitive releases.
- 2026-09-17 Global Strategic Alliance & MSA with Image Analysis Group Progress Report
- 2026-08-28 FY26 Full Year Results & Investor Webinar Web Cast | Preliminary Final Report
- 2026-08-28 FY26 Full Year Results & FY27 Guidance Investor Presentation Company Presentation | Preliminary Final Report
- 2026-08-28 Appendix 4E, Full Year Statutory Accounts & Annual Report Annual Report | Top 20 shareholders | Preliminary Final Report | Full Year Accounts | Full Year Audit Review | Full Year Directors' Statement | Full Year Directors' Report
- 2026-07-24 Quarterly Activities/Appendix 4C Cash Flow Report Commitments Test Entity - Fourth Quarter Activity Report | Commitments Test Entity - Fourth Quarter Cashflow Report
- 2026-06-09 Liver Fibrosis Device Progress & FY26 Portfolio Webinar
- 2026-05-05 Profit Guidance Upgrade
More Health Care stocks
Most traded in the same sector.